Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia

K. Srutova, N. Curik, P. Burda, F. Savvulidi, G. Silvestri, R. Trotta, H. Klamova, P. Pecherkova, Z. Sovova, J. Koblihova, T. Stopka, D. Perrotti, KM. Polakova,

. 2018 ; 103 (12) : 2016-2025. [pub] 20180726

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19045344

Grantová podpora
R01 CA163800 NCI NIH HHS - United States

The fusion oncoprotein BCR-ABL1 exhibits aberrant tyrosine kinase activity and it has been proposed that it deregulates signaling networks involving both transcription factors and non-coding microRNAs that result in chronic myeloid leukemia (CML). Previously, microRNA expression profiling showed deregulated expression of miR-150 and miR-155 in CML. In this study, we placed these findings into the broader context of the MYC/miR-150/MYB/miR-155/PU.1 oncogenic network. We propose that up-regulated MYC and miR-155 in CD34+ leukemic stem and progenitor cells, in concert with BCR-ABL1, impair the molecular mechanisms of myeloid differentiation associated with low miR-150 and PU.1 levels. We revealed that MYC directly occupied the -11.7 kb and -0.35 kb regulatory regions in the MIR150 gene. MYC occupancy was markedly increased through BCR-ABL1 activity, causing inhibition of MIR150 gene expression in CML CD34+ and CD34- cells. Furthermore, we found an association between reduced miR-150 levels in CML blast cells and their resistance to tyrosine kinase inhibitors (TKIs). Although TKIs successfully disrupted BCR-ABL1 kinase activity in proliferating CML cells, this treatment did not efficiently target quiescent leukemic stem cells. The study presents new evidence regarding the MYC/miR-150/MYB/miR-155/PU.1 leukemic network established by aberrant BCR-ABL1 activity. The key connecting nodes of this network may serve as potential druggable targets to overcome resistance of CML stem and progenitor cells.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045344
003      
CZ-PrNML
005      
20231102133617.0
007      
ta
008      
200109s2018 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2018.193086 $2 doi
035    __
$a (PubMed)30049824
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Srutova, Klara $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
245    10
$a BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia / $c K. Srutova, N. Curik, P. Burda, F. Savvulidi, G. Silvestri, R. Trotta, H. Klamova, P. Pecherkova, Z. Sovova, J. Koblihova, T. Stopka, D. Perrotti, KM. Polakova,
520    9_
$a The fusion oncoprotein BCR-ABL1 exhibits aberrant tyrosine kinase activity and it has been proposed that it deregulates signaling networks involving both transcription factors and non-coding microRNAs that result in chronic myeloid leukemia (CML). Previously, microRNA expression profiling showed deregulated expression of miR-150 and miR-155 in CML. In this study, we placed these findings into the broader context of the MYC/miR-150/MYB/miR-155/PU.1 oncogenic network. We propose that up-regulated MYC and miR-155 in CD34+ leukemic stem and progenitor cells, in concert with BCR-ABL1, impair the molecular mechanisms of myeloid differentiation associated with low miR-150 and PU.1 levels. We revealed that MYC directly occupied the -11.7 kb and -0.35 kb regulatory regions in the MIR150 gene. MYC occupancy was markedly increased through BCR-ABL1 activity, causing inhibition of MIR150 gene expression in CML CD34+ and CD34- cells. Furthermore, we found an association between reduced miR-150 levels in CML blast cells and their resistance to tyrosine kinase inhibitors (TKIs). Although TKIs successfully disrupted BCR-ABL1 kinase activity in proliferating CML cells, this treatment did not efficiently target quiescent leukemic stem cells. The study presents new evidence regarding the MYC/miR-150/MYB/miR-155/PU.1 leukemic network established by aberrant BCR-ABL1 activity. The key connecting nodes of this network may serve as potential druggable targets to overcome resistance of CML stem and progenitor cells.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a buněčná diferenciace $x účinky léků $x genetika $7 D002454
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $x genetika $7 D049109
650    _2
$a down regulace $x účinky léků $7 D015536
650    _2
$a chemorezistence $x účinky léků $x genetika $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a bcr-abl fúzní proteiny $x genetika $7 D016044
650    _2
$a regulace genové exprese u leukemie $x účinky léků $7 D015973
650    _2
$a geny myc $x genetika $7 D016259
650    _2
$a HL-60 buňky $7 D018922
650    _2
$a lidé $7 D006801
650    _2
$a buňky K562 $7 D020014
650    _2
$a chronická myeloidní leukemie $x farmakoterapie $x genetika $x patologie $7 D015464
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikro RNA $x genetika $7 D035683
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádorové kmenové buňky $x účinky léků $x metabolismus $7 D014411
650    _2
$a inhibitory proteinkinas $x farmakologie $7 D047428
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Curik, Nikola $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Institute of Pathological Physiology, First Medical Faculty, Charles University, Prague, Czech Republic.
700    1_
$a Burda, Pavel $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Institute of Pathological Physiology, First Medical Faculty, Charles University, Prague, Czech Republic.
700    1_
$a Savvulidi, Filipp $u Institute of Pathological Physiology, First Medical Faculty, Charles University, Prague, Czech Republic.
700    1_
$a Silvestri, Giovannino $u Department of Medicine, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Baltimore, MD, USA.
700    1_
$a Trotta, Rossana $u Department of Microbiology and Immunology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Baltimore, MD, USA.
700    1_
$a Klamova, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Institute of Clinical and Experimental Hematology, First Medical Faculty, Charles University, Prague, Czech Republic.
700    1_
$a Pecherková, Pavla, $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $d 1980- $7 ctu2013787641
700    1_
$a Sovova, Zofie $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Koblihova, Jitka $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Stopka, Tomas $u BIOCEV, First Medical Faculty, Charles University, Vestec, Czech Republic.
700    1_
$a Perrotti, Danilo $u Department of Medicine, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Baltimore, MD, USA.
700    1_
$a Polakova, Katerina Machova $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic katerina.machova@uhkt.cz. Institute of Clinical and Experimental Hematology, First Medical Faculty, Charles University, Prague, Czech Republic.
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 103, č. 12 (2018), s. 2016-2025
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30049824 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20231102133612 $b ABA008
999    __
$a ok $b bmc $g 1483613 $s 1084017
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 103 $c 12 $d 2016-2025 $e 20180726 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
GRA    __
$a R01 CA163800 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace